Concept · medicine
Hepatocellular carcinoma
3 studies
Hepatocellular carcinoma is the main primary liver cancer. Study layers here separate three claims: tumour EZH2 mRNA as a clinicopathological invasion marker, DNA methylation signatures that classify HCC tissue and track clinical correlates, and preclinical exosome delivery of miR-122 to sensitize HCC models to chemotherapy.
Students collapse “HCC biomarkers” and “HCC therapy ideas” into one story. A surgical expression association, an epigenetic classifier, and a mouse/cell chemosensitisation strategy answer different questions. Mixing them invents false agreement about diagnosis and treatment readiness.
Studies
3
Findings
3
3 supporting · 0 challenging · 4 qualifying citations
Open tensions
2
Currently
What we know
- Higher tumour EZH2 mRNA associates with portal-vein invasion after HCC resection.
- Validated DNA methylation signatures can separate HCC from surrounding liver.
- AMSC exosomes can deliver miR-122 and sensitise HCC models to chemotherapy.
Largest unresolved question
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
Common misconceptions
Any HCC molecular marker is ready to guide the same treatment decision.
Invasion-linked mRNA, tissue methylation classifiers, and preclinical miRNA delivery answer different questions. None automatically becomes a universal treatment rule.
Higher EZH2 always means worse survival after HCC surgery.
In this cohort it tracked portal-vein invasion, but disease-free survival did not differ significantly between high and low EZH2 groups.
miR-122 AMSC exosomes are an approved HCC chemo adjunct.
Evidence is preclinical (HepG2/xenograft). Authors frame a treatment strategy; patient RCTs and delivery/safety work remain required.
Related
Claim ledger
What the evidence shows
Drawn from 3 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
Higher tumour EZH2 mRNA associates with portal-vein invasion after HCC resection.
In 66 surgical HCC tumours, EZH2 mRNA exceeded matched nontumour liver and high expression tracked portal-vein invasion (79% vs 39%) without a significant disease-free survival split — a clinicopathological progression signal, not a proven survival assay in this cohort.
- DNA methylation signatures separate HCC from nearby liver— different molecular layer — promoter methylation signatures, not EZH2 mRNA invasion associations
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo— different question — preclinical chemosensitisation, not surgical clinicopathology
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Qualifiesdifferent molecular layer — promoter methylation signatures, not EZH2 mRNA invasion associations OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival miR-122 exosomes from fat stem cells sensitize HCC models to chemo Qualifiesdifferent question — preclinical chemosensitisation, not surgical clinicopathology Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes Validated DNA methylation signatures can separate HCC from surrounding liver.
Illumina promoter arrays in 30 paired HCC/surrounding samples produced a validated methylation signature that distinguished tumour from adjacent liver independent of major risk factors, with other panels linked to progression and survival after therapy.
- Higher tumour EZH2 tracks portal-vein invasion in HCC— related HCC progression theme, but single-gene mRNA vs multi-CpG epigenetic classifier
Study Role Design N Population Outcome DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival Higher tumour EZH2 tracks portal-vein invasion in HCC Qualifiesrelated HCC progression theme, but single-gene mRNA vs multi-CpG epigenetic classifier CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival AMSC exosomes can deliver miR-122 and sensitise HCC models to chemotherapy.
miR-122–loaded adipose MSC exosomes raised miR-122 in HepG2 cells, downregulated resistance-linked targets (including CCNG1/ADAM10/IGF1R), and increased chemosensitivity in vitro and in xenograft combinations — a preclinical strategy, not a finished patient protocol.
- Higher tumour EZH2 tracks portal-vein invasion in HCC— human surgical association study, not an exosome therapy experiment
Study Role Design N Population Outcome miR-122 exosomes from fat stem cells sensitize HCC models to chemo Supports Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes Higher tumour EZH2 tracks portal-vein invasion in HCC Qualifieshuman surgical association study, not an exosome therapy experiment CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
- DNA methylation signatures separate HCC from nearby liver
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival miR-122 exosomes from fat stem cells sensitize HCC models to chemo Supports Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
- DNA methylation signatures separate HCC from nearby liver
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Hepatocellular carcinoma
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
- Coverage updated · Concept page published
Papers
3 studies in this library bear on Hepatocellular carcinoma, ordered by citations.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Adipose MSC exosomes loaded with miR-122 delivered the microRNA into HepG2 cells, downregulated CCNG1/ADAM10/IGF1R, and increased chemosensitivity in vitro and in xenografts combined with agents such as sorafenib.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
In 66 resected HCC tumours, EZH2 mRNA was higher than in paired nontumour liver and high expression associated with portal-vein invasion (79% vs 39%), without a significant disease-free survival difference.
- DNA methylation signatures separate HCC from nearby liver
Promoter methylation arrays in 30 HCC tumours vs surrounding tissue produced a validated signature that distinguished HCC from adjacent liver (independent of major risk factors), with other methylation panels tracking risk factors, progression, and survival after therapy.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
Ask PaperFren about Hepatocellular carcinoma
Study this conceptflashcards and short-answer questions
Why can an EZH2 invasion association and a methylation tumour-vs-liver signature both be useful without being one test?
One links a single transcript to a pathological invasion feature in resected tumours; the other is a multi-CpG epigenetic classifier of tissue identity/clinical correlates. Different molecular layers and decision uses.
A student treats the miR-122 exosome paper as proof patients should receive MSC exosomes with sorafenib tomorrow. What limit blocks that leap?
The work is preclinical cell/xenograft chemosensitisation. Exosome-only tumour control was not significant vs vehicle in the cited comparison, and human dosing/safety/efficacy trials are still required.